Wednesday, October 06, 2021

Retail And Pharmaceutical Distribution Of Psychedelics Will Destroy Millions More Minds And Lives

caitlinjohnstone |   “Money has begun flowing into companies intending to monetize psychedelic therapy as new research has increasingly shown that blowing one’s mind can alter it for the better,” reads a new article for the Los Angeles Times titled “Money is pouring into psychedelics. Meet the mystical hedge fund investor bankrolling the boom.”

“This scientific and commercial excitement rests on research showing that psychedelics can supercharge mental health treatment for PTSD, depression, anxiety, addiction, and other chronic ailments of the mind, enabling patients to dive deep, confront their traumas and — a rarity for mental illnesses — return healed,” the article reads. “That goes for synthetic chemicals such as MDMA and ketamine as well as plant-derived drugs such as psilocybin (the active ingredient in magic mushrooms), the South American plant brew ayahuasca, and the West African root-derived substance iboga.”

LA Times’ Sam Dean shares the personal journey of hedge fund investor Sa’ad Shah and his involvement in what has become a multibillion-dollar psychedelics industry long before even the legal infrastructure necessary for such companies to turn a profit is in place. We learn of Shah’s experience with ayahuasca, his interest in mystical traditions and personal growth, and his conviction in the shift that has for the last few years been known as the psychedelic renaissance.

And then, about halfway down the article, we get to the actual meat of the matter:

“Shah welcomes big pharma and big institutions to enter the fray in the interest of spreading the chemical gospel far and wide. He sees the financial and therapeutic potential for psychedelics not in the cannabis model, which would make psychedelics broadly available for retail purchase, but in the pharmaceutical mode — psychedelics as prescribed drugs, with patent rights, administered in medical settings.”

That “with patent rights” bit right there is behind the so-called psychedelic renaissance we’ve been hearing so much about: “favoring the FDA regulatory route over the Oregon route,” as a psychiatrist cited in the article put it. It’s being driven not by the need to free human consciousness from the prohibition-induced coma it’s been under since the sixties so that we can collectively navigate through the many existential hurdles our species is fast approaching with wisdom and insight, but by the agenda to make rich people even richer by forcefully controlling psychedelic substances via the pharmaceutical industry.

0 comments:

Crackdowns On Pro-Palestinian Protest And Gaza Ethnic Cleansing

nakedcapitalism  |   Many US papers are giving front-page, above the fold treatment to university administrators going wild and calling in...